Form 8-K - Current report:
SEC Accession No. 0001193125-25-153576
Filing Date
2025-07-01
Accepted
2025-07-01 09:21:07
Documents
15
Period of Report
2025-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d82329d8k.htm   iXBRL 8-K 59068
2 EX-2.1 d82329dex21.htm EX-2.1 548077
3 EX-10.1 d82329dex101.htm EX-10.1 120066
4 EX-99.1 d82329dex991.htm EX-99.1 11787
  Complete submission text file 0001193125-25-153576.txt   1027776

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA igms-20250701.xsd EX-101.SCH 2492
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE igms-20250701_lab.xml EX-101.LAB 16425
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE igms-20250701_pre.xml EX-101.PRE 10318
18 EXTRACTED XBRL INSTANCE DOCUMENT d82329d8k_htm.xml XML 3169
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 251094388
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)